CHI Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

CHI Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$7.66M	Buy	215,000 +130,000	+153%	+$5.15M	3.04%	9
2023 Q2	$3.92M	Buy	+85,000	New	+$3.94M	1.19%	16
2021 Q2	–	Sell	-2,000	Closed	-$228K	–	21
2021 Q1	$228K	Sell	2,000 -1,000	-33%	-$136K	0.05%	21
2020 Q4	$415K	Sell	3,000 -4,500	-60%	-$534K	0.12%	19
2020 Q3	$616K	Sell	7,500 -5,500	-42%	-$456K	0.22%	18
2020 Q2	$1.02M	Sell	13,000 -26,362	-67%	-$1.74M	0.4%	14
2020 Q1	$1.75M	Buy	39,362 +862	+2%	+$44.8K	4.12%	7
2019 Q4	$1.64M	Buy	38,500 +14,500	+60%	+$598K	1.24%	7
2019 Q3	$1.03M	Buy	+24,000	New	+$1.3M	1%	11

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

CHI Advisors's RARE Position: Q3 2023 in Review

CHI Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 153% in Q3 2023, buying an estimated $5.15M and bringing the position to 215,000 shares worth $7.66M. The position accounts for 3.04% of the portfolio, ranked #9.

CHI Advisors first reported a position in RARE in Q3 2019 and has held it in 9 quarters since. 220 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

CHI Advisors held 215,000 shares of Ultragenyx Pharmaceutical worth $7.66M as of Q3 2023.
CHI Advisors bought 130,000 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $5.15M.
Ultragenyx Pharmaceutical made up 3.04% of CHI Advisors's portfolio in Q3 2023, its #9 holding.
CHI Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and has held it in 9 quarters since.
220 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.